ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Prepaid Expenses, Other
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Prepaid Expenses, Other of -$3.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpensesOther · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for the quarter ending 2026-06-30 was -$12.00M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for the quarter ending 2026-03-31 was $9.00M, a 47.06% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for the quarter ending 2025-12-31 was $2.74M, a 918.59% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for the quarter ending 2025-09-30 was -$9.74M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for fiscal 2025 was $10.00M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for fiscal 2024 was -$12.00M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for fiscal 2023 was -$15.00M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in prepaid expenses, other for fiscal 2022 was -$3.80M.
| Period end | Increase (Decrease) in Prepaid Expenses, Other 3 month | Increase (Decrease) in Prepaid Expenses, Other 3 month as first filed | Increase (Decrease) in Prepaid Expenses, Other 6 month | Increase (Decrease) in Prepaid Expenses, Other 6 month as first filed | Increase (Decrease) in Prepaid Expenses, Other 9 month | Increase (Decrease) in Prepaid Expenses, Other 12 month | Increase (Decrease) in Prepaid Expenses, Other 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.00M 10-Q · filed 2026-08-05 | -$260.00K derived: sum of 3 quarters · filed 2026-08-05 | -$10.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $9.00M 10-Q · filed 2026-05-06 | $11.74M derived: sum of 2 quarters · filed 2026-05-06 | $2.00M derived: sum of 3 quarters · filed 2026-05-06 | $2.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$7.00M derived: sum of 2 quarters · filed 2026-02-18 | -$7.00M derived: sum of 3 quarters · filed 2026-08-05 | $10.00M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | -$9.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$9.74M derived: sum of 2 quarters · filed 2026-08-05 | $7.26M 10-Q · filed 2025-11-05 | $7.53M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $17.00M 10-Q · filed 2026-08-05 | $17.16M 10-Q · filed 2025-08-06 | $17.27M derived: sum of 3 quarters · filed 2026-08-05 | $4.55M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $17.00M 10-Q · filed 2026-05-06 | $17.48M 10-Q · filed 2025-05-07 | $17.27M derived: sum of 2 quarters · filed 2026-05-06 | $4.55M derived: sum of 3 quarters · filed 2026-05-06 | $11.55M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$12.45M derived: sum of 2 quarters · filed 2026-02-18 | -$5.45M derived: sum of 3 quarters · filed 2026-02-18 | -$12.00M 10-K · filed 2026-02-18 | -$11.73M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | -$12.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$5.72M derived: sum of 2 quarters · filed 2025-11-05 | -$12.27M 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $449.00K 10-Q · filed 2025-08-06 | |||||
| 2024-03-31 | -$6.55M 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | -$15.00M 10-K · filed 2026-02-18 | -$15.32M 10-K · filed 2025-02-19 | |||||
| 2022-12-31 | -$3.80M 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |